131 related articles for article (PubMed ID: 1931616)
1. Thyroid dysfunction can predict response to immunotherapy with interleukin-2 and interferon-2 alpha.
Reid I; Sharpe I; McDevitt J; Maxwell W; Emmons R; Tanner WA; Monson JR
Br J Cancer; 1991 Nov; 64(5):915-8. PubMed ID: 1931616
[TBL] [Abstract][Full Text] [Related]
2. [Endocrine involvement in immunotherapy].
Tartour E; Schlumberger M; Dorval T; Baudin E; Fridman WH
Ann Endocrinol (Paris); 1995; 56(2):143-8. PubMed ID: 7755342
[TBL] [Abstract][Full Text] [Related]
3. Thyroid function abnormalities associated with the chronic outpatient administration of recombinant interleukin-2 and recombinant interferon-alpha.
Jacobs EL; Clare-Salzler MJ; Chopra IJ; Figlin RA
J Immunother (1991); 1991 Dec; 10(6):448-55. PubMed ID: 1768679
[TBL] [Abstract][Full Text] [Related]
4. Interleukin-2-induced thyroid dysfunction is correlated with treatment duration but not with tumor response.
Kruit WH; Bolhuis RL; Goey SH; Jansen RL; Eggermont AM; Batchelor D; Schmitz PI; Stoter G
J Clin Oncol; 1993 May; 11(5):921-4. PubMed ID: 8487055
[TBL] [Abstract][Full Text] [Related]
5. [Analysis of thyroid dysfunction and influencing factors in chronic hepatitis C patients treated with peg-IFNa-2a and ribavirin].
Huang YX; Chen XY; Ma LN; Yin JM; Ren S; Guo DD; Zheng YH
Zhonghua Gan Zang Bing Za Zhi; 2012 Mar; 20(3):216-20. PubMed ID: 22475143
[TBL] [Abstract][Full Text] [Related]
6. Suppressed thyroid-stimulating hormone secretion in patients treated with interleukin-2 and interferon-alpha 2b for metastatic melanoma.
Mönig H; Hauschild A; Lange S; Fölsch UR
Clin Investig; 1994 Dec; 72(12):975-8. PubMed ID: 7711430
[TBL] [Abstract][Full Text] [Related]
7. Thyroiditis after treatment with interleukin-2 and interferon alpha-2a.
Pichert G; Jost LM; Zöbeli L; Odermatt B; Pedia G; Stahel RA
Br J Cancer; 1990 Jul; 62(1):100-4. PubMed ID: 2390468
[TBL] [Abstract][Full Text] [Related]
8. Thyroid function and changes in ultrasound morphology during antiviral therapy with pegylated interferon and ribavirin in patients with chronic hepatitis C.
Friedrich-Rust M; Theobald J; Zeuzem S; Bojunga J
J Viral Hepat; 2009 Mar; 16(3):168-77. PubMed ID: 19175874
[TBL] [Abstract][Full Text] [Related]
9. Immunological effects of alternative weekly interferon-alpha-2b and low dose interleukin-2 in patients with cancer.
Fiorentino B; Di Stefano P; Giuliani C; Amatetti C; Tinari N; Natoli C; Garufi C; Iacobelli S
Br J Cancer; 1992 Nov; 66(5):981-3. PubMed ID: 1419647
[No Abstract] [Full Text] [Related]
10. Autoimmunity resulting from cytokine treatment predicts long-term survival in patients with metastatic renal cell cancer.
Franzke A; Peest D; Probst-Kepper M; Buer J; Kirchner GI; Brabant G; Kirchner H; Ganser A; Atzpodien J
J Clin Oncol; 1999 Feb; 17(2):529-33. PubMed ID: 10080596
[TBL] [Abstract][Full Text] [Related]
11. Incidence of and risk factors for thyroid dysfunction during peginterferon α and ribavirin treatment in patients with chronic hepatitis C.
Hwang Y; Kim W; Kwon SY; Yu HM; Kim JH; Choe WH
Korean J Intern Med; 2015 Nov; 30(6):792-800. PubMed ID: 26552454
[TBL] [Abstract][Full Text] [Related]
12. Immunochemotherapy with interleukin-2, interferon-alpha and 5-fluorouracil for progressive metastatic renal cell carcinoma: a multicenter phase II study. Dutch Immunotherapy Working Party.
van Herpen CM; Jansen RL; Kruit WH; Hoekman K; Groenewegen G; Osanto S; De Mulder PH
Br J Cancer; 2000 Feb; 82(4):772-6. PubMed ID: 10732744
[TBL] [Abstract][Full Text] [Related]
13. Thyroid dysfunction as an unintended side effect of anticancer drugs.
Torino F; Barnabei A; Paragliola R; Baldelli R; Appetecchia M; Corsello SM
Thyroid; 2013 Nov; 23(11):1345-66. PubMed ID: 23750887
[TBL] [Abstract][Full Text] [Related]
14. Incidence rate and risk factors for thyroid dysfunction during recombinant interleukin-2 therapy in advanced malignancies.
Vialettes B; Guillerand MA; Viens P; Stoppa AM; Baume D; Sauvan R; Pasquier J; San Marco M; Olive D; Maraninchi D
Acta Endocrinol (Copenh); 1993 Jul; 129(1):31-8. PubMed ID: 8351956
[TBL] [Abstract][Full Text] [Related]
15. Survival in renal cell carcinoma-a randomized evaluation of tamoxifen vs interleukin 2, alpha-interferon (leucocyte) and tamoxifen.
Henriksson R; Nilsson S; Colleen S; Wersäll P; Helsing M; Zimmerman R; Engman K
Br J Cancer; 1998 Apr; 77(8):1311-7. PubMed ID: 9579838
[TBL] [Abstract][Full Text] [Related]
16. Pilot study of interleukin-2 and lymphokine-activated killer cells combined with immunomodulatory doses of chemotherapy and sequenced with interferon alfa-2a in patients with metastatic melanoma and renal cell carcinoma.
Sznol M; Clark JW; Smith JW; Steis RG; Urba WJ; Rubinstein LV; VanderMolen LA; Janik J; Sharfman WH; Fenton RG
J Natl Cancer Inst; 1992 Jun; 84(12):929-37. PubMed ID: 1629914
[TBL] [Abstract][Full Text] [Related]
17. Patients treated with interferon-alpha, interferon-beta, and interleukin-2 have a different thyroid autoantibody pattern than patients suffering from endogenous autoimmune thyroid disease.
Schuppert F; Rambusch E; Kirchner H; Atzpodien J; Kohn LD; von zur Mühlen A
Thyroid; 1997 Dec; 7(6):837-42. PubMed ID: 9459625
[TBL] [Abstract][Full Text] [Related]
18. Rapidly progressive glomerulonephritis after immunotherapy for cancer.
Parker MG; Atkins MB; Ucci AA; Levey AS
J Am Soc Nephrol; 1995 Apr; 5(10):1740-4. PubMed ID: 7787140
[TBL] [Abstract][Full Text] [Related]
19. Thyroid functions in patients treated with interleukin-2 and lymphokine-activated killer cells.
Kung AW; Lai CL; Wong KL; Tam CF
Q J Med; 1992 Jan; 82(297):33-42. PubMed ID: 1332102
[TBL] [Abstract][Full Text] [Related]
20. Interferon-alpha induced thyroid dysfunction: three clinical presentations and a review of the literature.
Koh LK; Greenspan FS; Yeo PP
Thyroid; 1997 Dec; 7(6):891-6. PubMed ID: 9459633
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
